Sakar Healthcare Reports 95% Surge in Q1 Net Profit, EBITDA Grows Despite Margin Decline Jul 25, 2025
Sakar Healthcare Expands European Footprint with New Anti-Cancer Injection Approvals Jul 16, 2025
Sakar Healthcare Eyes EU Expansion with Anticipated MAS Approval for Oncology Products Jun 18, 2025
Sakar Healthcare Reports Impressive Q4 FY23 Results with Substantial Profit Growth May 15, 2025
More news about Sakar Healthcare
21Apr 25
Sakar Healthcare Achieves First EU Marketing Authorization for Oncology Injection
Sakar Healthcare Ltd has obtained its first Marketing Authorization (MA) in the European Union for an oncology injection. This approval marks a significant milestone in the company's international expansion, opening up opportunities in the European oncology market. The authorization demonstrates Sakar's ability to meet EU regulatory standards and strengthens its oncology product portfolio.
16Apr 25
Sakar Healthcare Expands Global Reach with 9 New Export Agreements
Sakar Healthcare Ltd has signed nine strategic agreements with partners in Europe and South America for exporting oncology products. This move marks a significant step in the company's global expansion strategy, particularly in the oncology segment. While financial details are undisclosed, the partnerships are expected to boost export volumes and revenue, diversify market presence, and strengthen the company's position in the specialized pharmaceutical market.